Oct 01, 2021 · 2022 ICD-10-CM Diagnosis Code C85.90: Non-Hodgkin lymphoma, unspecified, unspecified site ICD-10-CM Codes › C00-D49 Neoplasms › C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue › C85- Other specified and unspecified types of non-Hodgkin lymphoma › 2022 ICD-10-CM Diagnosis Code C85.90 2022 ICD-10-CM Diagnosis …
Cancer of the central nervous system, lymphoma; Primary central nervous system lymphoma ICD-10-CM Diagnosis Code C85.1 Unspecified B-cell lymphoma If B-cell lineage or involvement is mentioned in conjunction with a specific lymphoma, code to the more specific description. ICD-10-CM Diagnosis Code C82.20 [convert to ICD-9-CM]
Oct 01, 2021 · Lymphoma, marginal zone Marginal zone lymphoma Small lymphocytic b-cell lymphoma ICD-10-CM C83.00 is grouped within Diagnostic Related Group (s) (MS-DRG v39.0): 820 Lymphoma and leukemia with major o.r. Procedures with mcc 821 Lymphoma and leukemia with major o.r. Procedures with cc
C82.59 …… extranodal and solid organ sites C82.50 …… unspecified site C82.51 …… lymph nodes of head, face, and neck C82.52 …… intrathoracic lymph nodes C82.53 …… intra-abdominal lymph nodes C82.54 …… lymph nodes of axilla and upper limb C82.55 …… lymph nodes of inguinal region and lower limb C82.56 ...
C261 | Malignant neoplasm of spleen |
---|---|
C8198 | Hodgkin lymphoma, unspecified, lymph nodes of multiple sites |
C8199 | Hodgkin lymphoma, unspecified, extranodal and solid organ sites |
C8200 | Follicular lymphoma grade I, unspecified site |
C8201 | Follicular lymphoma grade I, lymph nodes of head, face, and neck |
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
Assign first the appropriate code from category T86.-, Complications of transplanted organs and tissue, followed by code C80.2, Malignant neoplasm associated with transplanted organ. Use an additional code for the specific malignancy.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only , the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present .
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
Code C80.1, Malignant ( primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
When an episode of care involves the surgical removal of a neoplasm, primary or secondary site, followed by adjunct chemotherapy or radiation treatment during the same episode of care , the neoplasm code should be assigned as principal or first-listed diagnosis, using codes in the 140-198 series or where appropriate in the 200-203 series.
Symptoms, signs, and ill-defined conditions listed in Chapter 16 characteristic of, or associated with, an existing primary or secondary site malignancy cannot be used to replace the malignancy as principal or first-listed diagnosis, regardless of the number of admissions or encounters for treatment and care of the neoplasm.
The American Health Information Management Association makes no representation or guarantee with respect to the contents herein and specifically disclaims any implied guarantee of suitability for any specific purpose. AHIMA has no liability or responsibility to any person or entity with respect to any loss or damage caused by the use of this audio seminar, including but not limited to any loss of revenue, interruption of service, loss of business, or indirect damages resulting from the use of this program. AHIMA makes no guarantee that the use of this program will prevent differences of opinion or disputes with Medicare or other third party payers as to the amount that will be paid to providers of service.
When admission/encounter is for management of an anemia associated with the malignancy, and the treatment is only for anemia, the appropriate anemia code (such as code 285.22, Anemia in neoplastic disease) is designated at the principal diagnosis and is followed by the appropriate code(s) for the malignan cy.
Reticuloendothelial and lymphatic system Blood-forming tissues Develops in a single site Or several sites simultaneously Tumor cells circulate in large numbers in the bloodstream and the lymphatic system
If no site is indicated for a lymphoma and it is suspected to be extranodal, code to C80.9 (unknown primary site ). Lymphomas are considered to be systemic (generalized) diseases in contrast to solid tumors, such as breast or stomach cancer.
If no site is indicated for a lymphoma and it is suspected to be extranodal, code to C80.9 (unknown primary site ). Lymphomas are considered to be systemic (generalized) diseases in contrast to solid tumors, such as breast or stomach cancer.
Lymphomas can also arise from lymphatic cells in organs, for example stomach or intestine.